Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

PURPOSE: In 2017, the Geneva Alzheimer’s disease (AD) strategic biomarker roadmap initiative proposed a framework of the systematic validation AD biomarkers to harmonize and accelerate their development and implementation in clinical practice. Here, we use this framework to examine the translatabili...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Nucl Med Mol Imaging
Autors principals: Bischof, Gérard N, Dodich, Alessandra, Boccardi, Marina, van Eimeren, Thilo, Festari, Cristina, Barthel, Henryk, Hansson, Oskar, Nordberg, Agneta, Ossenkoppele, Rik, Sabri, Osama, Giovanni, B Frisoni G, Garibotto, Valentina, Drzezga, Alexander
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2021
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8175320/
https://ncbi.nlm.nih.gov/pubmed/33590274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-05156-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars